Volume : 08, Issue : 07, July – 2021
Title:
03.EVALUATION OF DRUG UTILIZATION PATTERN OF HYPOLIPIDEMIC DRUGS AND DRUG RELATED PROBLEMS IN TERTIARY CARE HOSPITAL: PROSPECTIVE STUDY
Authors :
Deepa V Malipatil, Aswin Babu, Gopika Gopal, Sini Sakaria, M G Keshannavar*
Abstract :
Background: Hypolipidaemic drugs are the most commonly prescribed medications for cardiac and neurological disorders.Our study was focused on assessing the risk and benefits of hypolipidameic drugs along with their prescription patterns and their drug related problems.
Methods: An observational prospective study was carried out in 224 patients following the consent of protocol by the Institutional Review Board for evaluating the risk and benefits of hypolipidaemic drugs. Data were scrutinized using open epi version 2 software and WHO core prescribing indicators.
Results: Prescription pattern disclosed that 96.42% patients were advised with atorvastatin and was mostly prescribed for cardiovascular accident (31.25%) cases. On risk assessment based on plasma lipid levels 32.58%,13.39% patients had borderline high and high level of total cholesterol respectively; 51.78%, 6.69% patients had borderline high and high level of triglycerides respectively. 76.69% men and 82.41% women had low HDL cholesterol levels, while 16.07%,7.5% and 1.33% patients had borderline high and very high levels of LDL-C respectively. On benefit assessment based on plasma lipid profile, the mean value of LDL-C after treatment with statins showed a significant decrease in the LDL-C . B ased on the WHO core drug prescribing indicators the mean number of drugs per prescription was 4.2. Drugs prescribed by generic name and from essential drug list was 9.13 and 62.49% respectively. Percentage of encounters with an antibiotic and an injection prescribed was 49.55% and 91.07% respectively.
Conclusion: This study outlines that statins use have shown satisfactory benefit in the reduction LDL-C levels and other cardiovascular diseases. Similar studies ought to be done to enlighten the physicians regarding the advantages on prescribing hypolipidaemic drugs.
Keywords : Drug utilization ,CVD, Hypolipidaemic drugs, dyslipidemia
Cite This Article:
Please cite this article in press M G Keshannavar et al., Evaluation Of Drug Utilization Pattern Of Hypolipidemic Drugs And Drug Related Problems In Tertiary Care Hospital: Prospective Study.., Indo Am. J. P. Sci, 2021; 08(07).
Number of Downloads : 10
References:
REFERENCES:
1. Niharika Verma. Introduction to hyperlipidemia and its treatment: A review. International Journal of Current Pharmaceutical Research 2017;9(1):1
2. Sangeetha R, Satyajit M, Kumar JS, Jamuna R. Prescriptions patterns of hypolipidemic drugs in a tertiary care teaching hospital of Southern India. JDCR 2014;8(4):HC01- HC03.
3. Samantha Karr. Epidemiology and management of hyperlipdemia. A Journal Of Managed Care (AJMC) 2017;23:S0.
4. L. Maria Belalcazar, Christie M. Ballantyne. Defining specific goals of therapy in treating dyslipidemia in the patients with low high density lipoprotein cholesterol. Progress in Cardiovascular Diseases 1998;41(2):151-174.
5. Massoud Toussi, Deborah Layton. Study designs for post authorization safety studies. Post Authorization Safety Studies Of Medicinal Products 2018;107-163.
6. Helena Gama. Drug utilization studies. Arquivos De Medicina 2007;22(2/3):69-74.
7. Rima B.S, Bharat M.G, Sagun V.D. Drug utilization pattern among geriatrics patients assessed with anatomical therapeutic chemical classification/ Defined Daily Dose system in a rural tertiary care teaching hospital. International Journal of Nutrition, Pharmacology, Neurological Diseases 2012;2(3):258-265.
8. Sayer I, Karem H. Evaluation of the types and frequency of drug related problems and the association with gender in patients with chronic diseases attending a pimary health care center in Jordan. International Health 2016;8(6,1):423-426.
9. Rich ML,Ritterhoff RJ, Hoffmann RJ. A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy. Ann Intern Med 1950;33(6): 1459-67.
10. Jamtvedt G, Young JM, Kristoffersen DT. Audit abd feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2006; (2): CD000259
11. Davey P, Brown E, Fenelon L, Finch R. Interventions to improve antibiotic prescribing practices for hospitals inpatients. Cochrane Database Syst Rev 2005;(4):CD003543.
12. Winterstein AG, Sauer BC, Helper CD. Preventable drug related hospital admissions. Ann Pharmacother 2002;36(7,8):1238-48.
13. Lagnaoui R, Moore N, Fach J. Adverse drug reactions in a department of systemic diseases oriented internal medicine: prevelance, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000; 56(2):181-186
14. Charles BH, Linda MS. Opportunities responsibility in pharamaceutical care. Am J Hosp Pharmacy 1990;47:533-534.
15. Merilyn RS, David JK, Helene LL. A managed care model for implementation pharmacist directed services . J Managed Care Pharmacy 2005;11:333-44.
16. Hassar DA. Drug interaction. In: Gennaro L, Marderosian A, Hanson G. Remington. The science and practice of pharmacy . Philadelphia: Seventh ed: Lippincott Williams and Willinks, 2007; 1746-61.
17. Praveen KG, Arun K. Drug utilization and evaluation of HMG Co-A reductase inhibitors in tertiary care teaching hospital. IJOPP 2013;6(4):63
18. Seema G, Rajesh K, Dharminder K, Sanjeev B, Dinesh K, Nusrat KB, Surbhi M. Study of prescribing patterns of hypolipidemic agents in a tertiary care teaching hospital in North India. National Journal Of Physiology, Pharmacy And Pharmacology 2016;7(2):198
19. Kamlesh PP, Harsh MJ, Chintan K,Harsh S, Kartik NS, Varsha JP. Study of drug utilisation, morbidity pattern and cost of hypolipidemic agents in tertiary care hospital. IJBCP 2013;2(4):470
20. Sreedevi K, Venkateswara RJ, Fareedullah MD, Vjaykumar S. A study on prescription pattern of statins in cardiovascular disease. Der Pharmacia Lettre 2011;3(3):393-396
21. Mousa A, Anwar B, Yousef K. The prevelance of dyslipidemia among Jordanians. Journal of Lipids 2018
22. Preeja G Pillai. Studies on the prescriptions of cardiovascular units. Journal of Applied Pharmaceutical Science 2011;1(3):128-131.